Siemens Healthineers is debuting its first fully sealed 1.5 Tesla MRI scanner, designed to dramatically reduce its use of ...

After several years of development, Processa Pharmaceuticals has determined that the nearest milestone for anticancer asset ...

Medtronic and Philips have re-upped their long-running partnership focused on bundling vital sign sensors together with ...

Oncternal could receive up to $65 million in milestones if the programs are successful. Regulatory events account for $40 ...

Concentra Biosciences continues to scavenge for struggling biotechs, this time picking up antibody biotech IGM Biosciences ...

Sanofi has doubled down on its partnership with Adagene, investing $25 million in the biotech, taking up its option on a ...

Atai Life Sciences’ psychedelic drug has successfully reduced the symptoms of depression in a phase 2 study, triggering the ...

Argenx wants to get in on the macrocyclic peptide action, penning a deal worth $1.5 billion in biobucks with Californian ...

Apple Tree Partners’ life sciences venture fund has filed litigation against its controlling limited partners, claiming the ...

BerGenBio, reeling from the failure of its lead cancer drug, has opted to merge with fellow Norwegian cancer biotech Oncoinvent.

Shanghai and San Francisco Bay Area-based HanchorBio has already taken HCB101, an engineered SIRPα-IgG4 Fc fusion protein, into phase 2 trials for solid tumors and hematologic malignancies, including ...

AbbVie is on board with the idea. The Big Pharma will pay up to $2.1 billion in cash at closing to acquire Capstan. In return ...